Integrity Research Institute finds that the IRI OsteoPad with a 7.8 Hz slew rate (rise and fall times for the pulsed, time-varying magnetic signal) anticipated this “new” discovery of NASA, designed to be within the NASA frequency range for efficacy, and can therefore, now claim to regenerate cartilage. Our OsteoPad’s pulse rate also matches the earth’s Schumann Resonance, which is 7.8 Hertz and biocompatible. The other surprise is that our OsteoPad is capable of being “wrapped around synovial joints where cartilage-degrading inflammation is located” exactly as NASA predicts in the article below. - TV
Innovators at NASA Johnson Space Center researching time-variance magnetic field (TVMF) therapies have developed a pulsed electromagnetic field (PEMF) device that can alleviate cartilage degradation in synovial joints by promoting the growth of new cartilage.
Joint disorders result in intense pain. Noninvasive and painless regeneration of a patient’s own tissue offers fewer side-effects than surgical joint replacement or tissue engineering procedures. The PEMF device could be wrapped around synovial joints where cartilage-degrading inflammation is located.
In initial studies, cultured human chondrocyte cells (HCH) from patients with early-stage osteoarthritis were exposed to PEMF stimulation using a variety of tuned electro-magnetic pulse characteristics such as flux magnitude, slew rates (rise and fall times), frequency, wavelength, and duty cycle. Waveforms used in testing were monophasic, bi-phasic, square, sinusoidal, and triangular in nature.
Frequencies were generally low, ranging from 6-500 Hz, and the waveforms used high rising and falling slew rates on the order of Tesla/sec, promoting pulses or bursts. Cellular catabolic and anabolic gene expression analyses comprised of fold-change were accomplished by a survey of 47,000 human genes using an AFFYMETRIX Gene Array. Results show that variation of waveform used in PEMF therapies, independent of flux intensity, influences genetic regulation of HCH from patients with early-stage osteoarthritis. The device has potential to be used in the treatment of cartilage degenerative joint disorders in patients resulting from rheumatism, trauma, or surgery.
NASA is actively seeking licensees to commercialize this technology. Please contact NASA’s Licensing Concierge at Agency-Patent-Licensing@mail.nasa.gov [mailto:Agency-Patent-Licensing@mail.nasa.gov] or call at 202-358-7432 to initiate licensing discussions. For more information, visit here [https://technology.nasa.gov/patent/MSC-TOPS-96] .
NOTE: As a postscript, the reader may compare the above discovery with another more recent “New injectable cell therapy” to treat osteoarthritis, as reported in Medical Press (April 22, 2023). Wake Forest Institute for Regenerative Medicine (WFIRM) scientists created an injectable cell therapy to treat osteoarthritis that both reduces inflammation and also regenerates articular cartilage but we may want to ask if it is any better than the noninvasive joint therapy we review above. The synovial fluid treatment of Wake Forest reduced inflammation, which coincidentally, was found in an earlier patented discovery by NASA with fast rise time (slew rate) PEMF in the nanosecond range. This fast rise time activates the heat shock protein (HSP70) which Dr. Glen Gordon thereby popularized by integrating it into his Empulse invention that is now evolved into the IRI EM Pulser 78 and OsteoPad products.